Phase I trial and correlative laboratory studies of bryostatin 1 (NSC 339555) and high-dose 1-B-D-arabinofuranosylcytosine in patients with refractory acute leukemia

Clinical Cancer Research

Volumn 8, Issue 7, 2002, Pages 2123-2133

  Cragg, Louise H ^a   Andreeff, Michael ^c   Feldman, Eric ^b   Roberts, John ^a   Murgo, Anthony ^d   Winning, Mary ^a   Tombes, Mary Beth ^a   Roboz, Gail ^b   Kramer, Lora ^a   Grant, Steven ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^d NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BRYOSTATIN 1; CYTARABINE; LACTONE; MACROLIDE; PROTEIN KINASE C; FIACITABINE; NSC 339555;

ACUTE DISEASE; ACUTE LYMPHOCYTIC LEUKEMIA; ADULT; AGED; APOPTOSIS; ARTICLE; CELL CULTURE; CLINICAL TRIAL; COMPARATIVE STUDY; DRUG EFFECT; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; METABOLISM; MIDDLE AGED; MYELOID LEUKEMIA; PATHOLOGY; PHASE 1 CLINICAL TRIAL; ACUTE LEUKEMIA; AUTOLOGOUS BONE MARROW TRANSPLANTATION; BLEEDING; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; FATIGUE; HIGH RISK PATIENT; HISTOPATHOLOGY; HYPERBILIRUBINEMIA; INFECTION; LIVER TOXICITY; LUNG TOXICITY; MAXIMUM TOLERATED DOSE; METABOLIC DISORDER; MUCOSA INFLAMMATION; MYALGIA; NAUSEA; NEUTROPENIA; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; RELAPSE; REMISSION; THROMBOCYTOPENIA; VOMITING;

ACUTE DISEASE; ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CYTARABINE; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; LACTONES; LEUKEMIA, LYMPHOCYTIC, ACUTE; LEUKEMIA, MYELOID; MACROLIDES; MALE; MIDDLE AGED; PROTEIN KINASE C; TUMOR CELLS, CULTURED; COMPARATIVE STUDY; HUMAN; MIDDLE AGE; SUPPORT, NON-U.S. GOV'T; SUPPORT, U.S. GOV'T, P.H.S.;

EID: 0035992301     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Cytosine arabinoside in the treatment of acute myeloid leukemia: The role and place of high-dose regimens
2. Isolation and characterization of a deoxycytidine kinase-deficient human promyelocytic leukemic cell line highly resistant to 1-β-D-arabinofuranosylcytosine
3. Ara-C: Cellular and molecular pharmacology
4. Overexpression of Bcl-X(L) inhibits Ara-C-induced mitochondrial loss of cytochrome c and other perturbations that activate the molecular cascade of apoptosis
5. Effect of dose on the pharmacokinetic and pharmacodynamic effects of cytarabine
6. A pilot study of high-dose 1-β-D-arabinofuranosylcytosine for acute leukemia and refractory lymphoma: Clinical response and pharmacology
7. Curative chemotherapy for acute myeloid leukemia: The development of high-dose ara-C from the laboratory to bedside
8. Differential effects of bryostatin 1 and phorbol ester on human breast cancer cell lines
9. The bryostatins inhibit growth of B16/F10 melanoma cells in vitro through a protein kinase C-independent mechanism: Dissociation of activities using 26-epi-bryostatin 1
10. Preclinical evaluation of bryostatin as an anticancer agent against several murine tumor cell lines: In vitro versus in vivo activity
11. Varied differentiation responses of human leukemias to bryostatin 1
12. Human THP-1 monocytic leukemic cells induced to undergo monocytic differentiation by bryostatin I are refractory to proteasome inhibitor-induced apoptosis
13. Two protein kinase C activators, bryostatin-1 and phorbol-12-myristate-13-acetate, have different effects on haemopoietic cell proliferation and differentiation
14. Divergent effects of bryostatin 1 and phorbol myristate acetate on cell cycle arrest and maturation in human myelomonocytic leukemia cells (U937)
15. Bryostatin 1, a unique biologic response modifier: Anti-leukemic activity in vitro
16. Effect of a combined exposure to cytosine arabinoside, bryostatin 1, and recombinant granulocyte-macrophage colony-stimulating factor on the clonogenic growth in vitro of normal and leukemic human hematopoietic progenitor cells
17. A phase I trial of bryostatin 1 in patients with advanced malignancy using a 24 hour intravenous infusion
18. Phase I study of bryostatin 1: Assessment of interleukin 6 and tumor necrosis factor α induction in vivo
19. Immunomodulation in patients receiving intravenous Bryostatin 1 in a phase I clinical study: Comparison with effects of Bryostatin 1 on lymphocyte function in vitro
20. A Phase I trial of bryostatin-1 in children with refractory solid tumors: A Pediatric Oncology Group study
21. Phase I study of bryostatin 1 in patients with relapsed non-Hodgkin's lymphoma and chronic lymphocytic leukemia
22. Effects of bryostatin 1 and other pharmacological activators of protein kinase C on 1-[β-D-arabinofuranosyl]cytosine-induced apoptosis in HL-60 human promyelocytic leukemia cells
23. Protein kinase C and lipid signaling for sustained cellular responses
24. Differential regulation of protein kinase C isozymes by bryostatin 1and phorbol 12-myristate 13-acetate in NIH 3T3 fibroblasts
25. Ubiquitination of protein kinase C-α and degradation by the proteasome
26. Rescue from programmed cell death in leukemic and normal myeloid cells
27. Induction of apoptotic DNA fragmentation and cell death in HL-60 human promyelocytic leukemia cells by pharmacological inhibitors of protein kinase C
28. Induction of a common pathway of apoptosis by staurosporine
29. Modulation of 1-[β-D-arahinofuranosyl] cytosine-induced apoptosis in human myeloid leukemia cells by staurosporine and other pharmacological inhibitors of protein kinase C
30. Comparison of the induction of apoptosis in human leukemic cell lines by 2′, 2′-difluorodeoxycytidine (gemcitabine) and cytosine arabinoside
31. Agents that down-regulate or inhibit protein kinase C circumvent resistance to 1-[β-D-arabinofuranosylcytosine-induced apoptosis in human leukemia cells that overexpress Bcl-2
32. Modulation of protein kinase C activity and calcium-sensitive isoform expression in human myeloid leukemia cells by bryostatin 1: Relationship to differentiation and ara-C-induced apoptosis
33. Induction of cell differentiation potentiates apoptosis triggered by prior exposure to DNA-damaging drugs
34. Phase Ib trial of bryostatin 1 in patients with refractory malignancies
35. Treatment of poor risk acute leukemia with sequential high-dose ARA-C and asparaginase
36. Superiority of high-dose over intermediate-dose cytosine arabinoside in the treatment of patients with high-risk acute myeloid leukemia: Results of an age-adjusted prospective randomized comparison
37. Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia
38. The use of 7-amino actinomycin D in identifying apoptosis: Simplicity of use and broad spectrum of application compared with other techniques
39. Comparison of methods based on annexin-V binding. DNA content or TUNEL for evaluating cell death in HL-60 and adherent MCF-7 cells
40. Contributions of host- and disease-related attributes to the outcome of patients with acute myelogenous leukemia
41. Evidence of a functional role for the cyclin-dependent kinase inhibitor p21CIP1 in leukemic cell (U937) differentiation induced by low concentrations of 1-β-D-arabinofuranosylcytosine
42. Cytosine arabinoside in the management of recurrent leukaemia
43. Synergy between high-dose cytarabine and asparaginase in the treatment of adults with refractory and relapsed acute myelogenous leukemia-a Cancer and Leukemia Group B Study
44. Randomized trial of high-dose cytarabine versus amsacrine in acute myelogenous leukemia in relapse: A Leukemia Intergroup Study
45. Prognostic factors in acute myelogenous leukemia
46. High-performance liquid chromatographic assay for the novel antitumor drug, bryostatin-1, incorporating a serum extraction technique
47. Effects of GM-CSF on Ki67 expression and cell cycle traverse in acute myelogenous leukemia specimens and cell lines
48. Nucleoside analogues: Mechanisms of drug resistance and reversal strategies
49. Apoptotic cell death during treatment of leukemias
50. Mechanisms for recognition and phagocytosis of apoptotic lymphocytes by macrophages